News articles about Amphastar Pharmaceuticals (NASDAQ:AMPH) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 43.634329645378 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down $0.57 during trading hours on Friday, reaching $18.37. The company had a trading volume of 134,036 shares, compared to its average volume of 148,144. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $19.95. The company has a market capitalization of $870.78, a PE ratio of 126.27, a P/E/G ratio of 1.33 and a beta of 1.51. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. Amphastar Pharmaceuticals’s revenue was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.14 earnings per share. sell-side analysts anticipate that Amphastar Pharmaceuticals will post -0.04 EPS for the current fiscal year.
Several research firms have issued reports on AMPH. Piper Jaffray Companies reissued a “buy” rating and set a $26.00 price target on shares of Amphastar Pharmaceuticals in a report on Tuesday. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective for the company in a research note on Tuesday, January 23rd. BidaskClub upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 19th. Needham & Company LLC boosted their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, BMO Capital Markets boosted their target price on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, November 10th. Two analysts have rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $20.83.
In other news, CFO William J. Peters sold 6,226 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.67, for a total value of $122,465.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $18.55, for a total value of $145,840.10. Following the completion of the transaction, the director now owns 31,978 shares of the company’s stock, valued at approximately $593,191.90. The disclosure for this sale can be found here. Insiders have sold a total of 83,828 shares of company stock worth $1,589,659 in the last ninety days. Insiders own 11.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/03/amphastar-pharmaceuticals-amph-earns-daily-coverage-optimism-score-of-0-20.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.